Regeneron reports Eylea sales, introduces 2013 guidance

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported $276 million in 4Q12 net sales of ophthalmic drug Eylea aflibercept, up 13% over 3Q12. The biotech, which recorded 2012 U.S. sales of $838 million for Eylea, also introduced 2013 U.S. sales guidance for the drug of $1.2-$1.3 billion. A Brean Capital analyst said the 4Q12 Eylea sales beat the Street's estimate of $267 million, while the 2013 guidance is in line with the Street's estimate of $1.2 billion. The details came during a presentation on Tuesday at the JPMorgan Healthcare Conference.

Eylea, which was launched in November 2011, is approved in the U.S. to treat wet age-related macular degeneration (AMD) and macular edema following central retinal vein occlusion (CRVO), and in the EU to treat wet AMD. Regeneron has rights to Eylea in the U.S., while Bayer AG (Xetra:BAYN) has rights to market the product elsewhere. ...